| <DIV>环球医学据悉，辉瑞公司日前宣布了关于Lyrica（普瑞巴林）胶囊治疗广泛性焦虑症（GAD）患者的长期安全性和有效性研究（A0081147）的最新结果，研究结果显示在接受3个月和6个月Lyrica治疗后减少Lyrica用量，患者停药症状很低。 </DIV>
<DIV align=left>欧洲药品管理局（EMA）要求验证接受长时间Lyrica治疗后的GAD患者针对停药症状（包括焦虑反弹）治疗的剂量和持续时间的关系。辉瑞公司将继续进一步分析这些最新结果。</DIV>
<DIV align=left>在欧盟和世界各地其他几个地区（不包括美国），Lyrica被批准用于治疗成年GAD患者。<BR><BR>GAD是一种以过度焦虑和烦恼持续至少6个月为特征的慢性、使人衰弱的疾病。GAD的症状持续时间往往超过五年，症状不仅涉及心理的（焦虑情绪、高度恐惧、紧张的心情，注意力难以集中），也包括生理的（疲劳、疼痛、无力、肠胃不适、心悸、失眠和烦躁的感觉）。（环球医学）</DIV>
<P style="TEXT-ALIGN: center">Top-line results in Pfizer Lyrica long term safety study for Generalized Anxiety Disorder</P>
<P>Pfizer Inc. (NYSE: PFE) announced today that top-line results for Lyrica® (pregabalin) capsules Study A0081147 - Long Term Safety and Efficacy of Pregabalin in Subjects with Generalized Anxiety Disorder (GAD) - demonstrate that drug discontinuation symptoms were low after tapering Lyrica treatment following three months and six months in GAD patients.</P>
<P>The European Medicines Agency (EMA) requested this study to investigate the relationship between dose and duration of treatment on discontinuation symptoms, including rebound anxiety, following long-term treatment with Lyrica in GAD patients. Pfizer will continue to further analyze these top-line results.</P>
<P>Lyrica is approved for the treatment of GAD in adults in the European Union and several other regions around the world, but not in the United States.</P>
<P>GAD is a chronic, debilitating illness characterized by excessive anxiety and worry for at least six months in duration. Often lasting longer than five years, GAD symptoms are both psychological (anxious mood, heightened fears, feelings of tension, difficulty concentrating) and physical (fatigue, pain, feelings of weakness, gastrointestinal disturbance, palpitations, sleep disturbance and restlessness).</P>
<P>相关链接：<SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>http://www.news-medical.net/news/20120723/Top-line-results-in-Pfizers-Lyrica-long-term-safety-study-for-Generalized-Anxiety-Disorder.aspx</FONT></SPAN></P> |
